商品名：Antepsin*, Antepsin suspension*, Carafate*
In an acidic medium an aluminium ion detaches from the compound, leaving a very polar, relatively non-absorbable ion. This ion then binds to proteinaceous exudates in the upper GI tract, forming a chemical diffusion barrier over ulcer sites, preventing further erosion from acid, pepsin and bile salts. However, its major action appears to relate to stimulation of mucosal defences and repair mechanisms (stimulation of bicarbonate and PGE production and binding of epidermal growth factor). These ef
Treatment of oesophageal, gastric and duodenal ulceration, used with an H2 receptor antagonist or proton pump inhibitor but given separately. The efficacy of sucralfate as a phosphate binder in renal failure is uncertain.
劑量數字暫停提供：VetPro 的劑量改依 DRUGAPI 藥物資料庫對外的內容，DRUGAPI 目前不提供可直接計算的劑量。下方列出 DRUGAPI 的審查結論與劑量審查引用的來源；計算機可手動輸入劑量換算。
核對 succinylcholine 活性基團、精確鹽類、水合物、濃度、包裝、商品、效期、保存狀態與法域身分。 核對物種、品種、個體、年齡、體況、程序、肌病或去神經狀態、燒傷或創傷、電解質、膽鹼酯酶、惡性高熱風險、共病與共用藥物。 先閉合全身麻醉、鎮痛、意識深度、專任人員、氣道、氧合、正壓通氣、循環與直接神經肌肉監測契約；麻痺不得用來替代任何一項。 在產品、病例、時程、禁忌、監測、反應、失敗與救援契約未全部閉合前，不產生劑量、處方、重複使用、反轉、儲存或自動交互作用。
依出現頻率分組；嚴重副作用獨立列出，臨床上需立即辨識。
renal